Compare TSSI & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSSI | VCRE |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 271.7M |
| IPO Year | 2005 | 2026 |
| Metric | TSSI | VCRE |
|---|---|---|
| Price | $6.79 | $9.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $16.50 | ★ $29.97 |
| AVG Volume (30 Days) | ★ 782.0K | 20.2K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.33 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $245,719,000.00 | N/A |
| Revenue This Year | N/A | $101.29 |
| Revenue Next Year | $8.51 | $481.15 |
| P/E Ratio | $53.92 | ★ N/A |
| Revenue Growth | ★ 65.86 | N/A |
| 52 Week Low | $6.63 | $7.88 |
| 52 Week High | $17.77 | $14.01 |
| Indicator | TSSI | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 38.25 | 45.55 |
| Support Level | N/A | $8.70 |
| Resistance Level | $10.52 | $9.64 |
| Average True Range (ATR) | 0.44 | 0.51 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 33.28 | 19.38 |
TSS Inc provides a comprehensive suite of services for the integration of complex Artificial Intelligence (AI) technologies, planning, design, deployment, maintenance, and refresh of end-user and enterprise systems, including the mission-critical facilities that are housed. It provides a single-source solution for enabling technologies in data centers, operations centers, network facilities, server rooms, security operations centers, communications facilities, and the infrastructure systems that are critical to their functions. Services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.